Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel Free FDBK Stock Alerts

Feedback (FDBK) Competitors

Feedback logo
GBX 7.80 +0.10 (+1.30%)
As of 05:12 AM Eastern
Compare

FDBK vs. INHC, RENX, IQAI, DVRG, and SENS

Should you buy Feedback stock or one of its competitors? MarketBeat compares Feedback with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Feedback include Induction Healthcare Group (INHC), Renalytix (RENX), IQ-AI (IQAI), DeepVerge (DVRG), and Sensyne Health (SENS). These companies are all part of the "health information services" industry.

How does Feedback compare to Induction Healthcare Group?

Feedback (LON:FDBK) and Induction Healthcare Group (LON:INHC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Induction Healthcare Group has a net margin of -23.86% compared to Feedback's net margin of -845.25%. Induction Healthcare Group's return on equity of -14.58% beat Feedback's return on equity.

Company Net Margins Return on Equity Return on Assets
Feedback-845.25% -135.17% -22.99%
Induction Healthcare Group -23.86%-14.58%-7.32%

Induction Healthcare Group has higher revenue and earnings than Feedback. Induction Healthcare Group is trading at a lower price-to-earnings ratio than Feedback, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Feedback£849.62K4.02-£10.84M-£15.74N/A
Induction Healthcare Group£12.57M0.72-£5.12M-£5.54N/A

Feedback has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Induction Healthcare Group has a beta of -0.41, meaning that its stock price is 141% less volatile than the broader market.

In the previous week, Feedback's average media sentiment score of 0.00 equaled Induction Healthcare Group'saverage media sentiment score.

Company Overall Sentiment
Feedback Neutral
Induction Healthcare Group Neutral

35.7% of Feedback shares are held by institutional investors. Comparatively, 46.3% of Induction Healthcare Group shares are held by institutional investors. 8.0% of Feedback shares are held by insiders. Comparatively, 54.6% of Induction Healthcare Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Induction Healthcare Group beats Feedback on 8 of the 11 factors compared between the two stocks.

How does Feedback compare to Renalytix?

Feedback (LON:FDBK) and Renalytix (LON:RENX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Feedback has higher earnings, but lower revenue than Renalytix. Feedback is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Feedback£849.62K4.02-£10.84M-£15.74N/A
Renalytix£3.30M2.33-£109.93M-£4.00N/A

Renalytix has a net margin of -680.00% compared to Feedback's net margin of -845.25%. Renalytix's return on equity of 274.67% beat Feedback's return on equity.

Company Net Margins Return on Equity Return on Assets
Feedback-845.25% -135.17% -22.99%
Renalytix -680.00%274.67%-93.54%

35.7% of Feedback shares are owned by institutional investors. Comparatively, 14.0% of Renalytix shares are owned by institutional investors. 8.0% of Feedback shares are owned by insiders. Comparatively, 5.1% of Renalytix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Feedback's average media sentiment score of 0.00 equaled Renalytix'saverage media sentiment score.

Company Overall Sentiment
Feedback Neutral
Renalytix Neutral

Feedback has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Renalytix has a beta of 1.974, suggesting that its stock price is 97% more volatile than the broader market.

Summary

Renalytix beats Feedback on 6 of the 11 factors compared between the two stocks.

How does Feedback compare to IQ-AI?

IQ-AI (LON:IQAI) and Feedback (LON:FDBK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

IQ-AI has a net margin of -77.52% compared to Feedback's net margin of -845.25%. Feedback's return on equity of -135.17% beat IQ-AI's return on equity.

Company Net Margins Return on Equity Return on Assets
IQ-AI-77.52% -140.75% -22.03%
Feedback -845.25%-135.17%-22.99%

In the previous week, IQ-AI's average media sentiment score of 0.00 equaled Feedback'saverage media sentiment score.

Company Overall Sentiment
IQ-AI Neutral
Feedback Neutral

IQ-AI has higher earnings, but lower revenue than Feedback.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IQ-AI£538.19K3.30N/AN/AN/A
Feedback£849.62K4.02-£10.84M-£15.74N/A

35.7% of Feedback shares are owned by institutional investors. 66.0% of IQ-AI shares are owned by insiders. Comparatively, 8.0% of Feedback shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

IQ-AI has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market. Comparatively, Feedback has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

Summary

Feedback beats IQ-AI on 5 of the 9 factors compared between the two stocks.

How does Feedback compare to DeepVerge?

DeepVerge (LON:DVRG) and Feedback (LON:FDBK) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

DeepVerge has higher revenue and earnings than Feedback. Feedback is trading at a lower price-to-earnings ratio than DeepVerge, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DeepVerge£12.41M0.00-£2.46M-£0.01N/A
Feedback£849.62K4.02-£10.84M-£15.74N/A

DeepVerge has a net margin of -19.81% compared to Feedback's net margin of -845.25%. DeepVerge's return on equity of -10.27% beat Feedback's return on equity.

Company Net Margins Return on Equity Return on Assets
DeepVerge-19.81% -10.27% -5.56%
Feedback -845.25%-135.17%-22.99%

4.2% of DeepVerge shares are held by institutional investors. Comparatively, 35.7% of Feedback shares are held by institutional investors. 9.5% of DeepVerge shares are held by insiders. Comparatively, 8.0% of Feedback shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, DeepVerge's average media sentiment score of 0.00 equaled Feedback'saverage media sentiment score.

Company Overall Sentiment
DeepVerge Neutral
Feedback Neutral

DeepVerge has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Feedback has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

Summary

DeepVerge beats Feedback on 8 of the 10 factors compared between the two stocks.

How does Feedback compare to Sensyne Health?

Sensyne Health (LON:SENS) and Feedback (LON:FDBK) are both small-cap health information services industry companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

Sensyne Health has a net margin of 0.00% compared to Feedback's net margin of -845.25%. Sensyne Health's return on equity of 0.00% beat Feedback's return on equity.

Company Net Margins Return on Equity Return on Assets
Sensyne HealthN/A N/A N/A
Feedback -845.25%-135.17%-22.99%

In the previous week, Sensyne Health's average media sentiment score of 0.00 equaled Feedback'saverage media sentiment score.

Company Overall Sentiment
Sensyne Health Neutral
Feedback Neutral

35.7% of Feedback shares are held by institutional investors. 8.0% of Feedback shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Sensyne Health has higher revenue and earnings than Feedback. Feedback is trading at a lower price-to-earnings ratio than Sensyne Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sensyne Health£7.81M0.00N/A-£22.10N/A
Feedback£849.62K4.02-£10.84M-£15.74N/A

Summary

Sensyne Health beats Feedback on 5 of the 8 factors compared between the two stocks.

Get Feedback News Delivered to You Automatically

Sign up to receive the latest news and ratings for FDBK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FDBK vs. The Competition

Export
MetricFeedbackHealth Information Services IndustryMedical SectorLON Exchange
Market Cap£3.42M£332.74M£6.33B£2.79B
Dividend Yield4.56%5.59%2.69%6.13%
P/E Ratio-0.50196.2221.02364.91
Price / Sales4.02131.19558.8487,573.60
Price / Cash1.1247.1442.3127.85
Price / Book0.145.579.937.84
Net Income-£10.84M-£22.78M£3.56B£5.88B
7 Day Performance-3.70%1.34%-0.44%6.80%
1 Month Performance-17.89%0.52%4.58%10.02%
1 Year Performance-46.94%-10.22%27.57%75.92%

Feedback Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FDBK
Feedback
N/AGBX 7.80
+1.3%		N/A-46.9%£3.42M£849.62KN/A24
INHC
Induction Healthcare Group
N/AGBX 9.75
flat		N/A+4.2%£9.00M£12.57MN/A74
RENX
Renalytix
N/AGBX 1.60
-11.1%		N/A-75.2%£6.99M£3.30MN/A102
IQAI
IQ-AI
N/AGBX 0.80
flat		N/A+0.0%£1.77M£538.19KN/A6
DVRG
DeepVerge
N/AN/AN/AN/A£1.14M£12.41MN/A73

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:FDBK) was last updated on 6/3/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel